Imiquimod 5% cream is an acceptable treatment option for external anogenital warts in uncircumcised males

J Eur Acad Dermatol Venereol. 2002 Jan;16(1):58-62. doi: 10.1046/j.1468-3083.2002.00366.x.

Abstract

Objectives: To determine the safety and efficacy of imiquimod (Aldara) 5% cream in the treatment of prepuce-associated warts in uncircumcised males.

Methods: An open-label study in six UK medical centres with 35 uncircumcised males with prepuce-associated warts treated with imiquimod 5% cream three times per week for up to 16 weeks. Other anogenital warts were also treated.

Results: Three times weekly application of imiquimod was found to be safe, with erythema as the most commonly reported local skin reaction. Forty per cent of patients had complete clearance of anogenital warts within 16 weeks.

Conclusions: Imiquimod cream at a dosing regimen of three times per week, is effective and has an acceptable safety profile in the treatment of prepuce associated warts and other external anogenital warts in uncircumcised males.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Aminoquinolines / adverse effects
  • Aminoquinolines / therapeutic use*
  • Condylomata Acuminata / drug therapy*
  • Humans
  • Imiquimod
  • Interferon Inducers / adverse effects
  • Interferon Inducers / therapeutic use*
  • Male
  • Middle Aged
  • Ointments
  • Penile Diseases / drug therapy*
  • Treatment Outcome

Substances

  • Aminoquinolines
  • Interferon Inducers
  • Ointments
  • Imiquimod